Ads
related to: irritable bowel syndrome patient information leaflet fda- ArdelyxAssist™ Program
Learn More About The
Patient Support Program
- Copay Card
See How Much Your Patients
Could Save With IBSRELA®
- Mechanism Of Action
View MOA Information To See
How IBSRELA® Works
- Prescribing IBSRELA®
Learn More About Prescribing
IBSRELA®. Visit Our Website
- Safety Information
Important Safety Information
And Possible Adverse Effects
- Resources
Helpful Resources For You,
Your Practice, And Your Patients
- ArdelyxAssist™ Program
Search results
Results From The WOW.Com Content Network
Linaclotide, (sold under the brand name Linzess in the US and Mexico, and as Constella elsewhere) [6] is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause.
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by a group of symptoms that commonly include abdominal pain, abdominal bloating and changes in the consistency of bowel movements. [1] These symptoms may occur over a long time, sometimes for years. [2]
A combination of alverine citrate and simeticone (ACS) for irritable bowel syndrome therapy were compared with placebo in a phase IV clinical trial. [8] At week 4, the alverine citrate and simeticone group had lower VAS scores for abdominal pain/discomfort (median: 40 mm vs. 50 mm, P = 0.047) and higher responder rate (46.8% vs. 34.3%, OR = 1.3; P = 0.01) as compared with the placebo group.
Eluxadoline, sold under the brand names Viberzi and Truberzi, [3] is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). [4] It was approved for use in the United States in 2015. [5] The drug originated from Janssen Pharmaceutica and was ...
Mebeverine is used to alleviate some of the symptoms of irritable bowel syndrome (IBS) and related conditions; specifically stomach pain and cramps, persistent diarrhoea, and flatulence. [2] Historically data from controlled clinical trials have not found a difference from placebo or statistically significant results in the global improvement ...
Rifaximin is used for the treatment of irritable bowel syndrome (IBS). It possesses anti-inflammatory and antibacterial properties, and is a non-absorbable antibiotic that acts locally in the gut. These properties make it efficacious in relieving chronic functional symptoms of non-constipation type irritable bowel syndrome. [8]
Ad
related to: irritable bowel syndrome patient information leaflet fda